Actively Recruiting
Efficacy of Methylprednisolone Pulses in Neuroendocrine Celles Hyperplasia of Infancy : An Early Phase Study
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-08-27
18
Participants Needed
1
Research Sites
191 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Childhood interstitial lung diseases (chILD) are a heterogeneous group of rare and severe disorders with an estimated prevalence of 1/100,000. Among them, neuroendocrine cells hyperplasia of infancy (NEHI), also called persistent tachypnoea of infancy (PTI), is one of the most common aetiology (up to 16% of the cases). NEHI involves young infants (median age at onset 3 to 6 months) with tachypnoea, hypoxemia, crackles, retractions, failure to thrive and specific localizations of ground glass opacities (GGO) on chest CT-scan (paramediastinal areas and anterior lobes (right middle lobe and lingula). At diagnosis, most patients (50 to 100%) require oxygen supplementation that usually lasts for months to years, sometimes associated with nutritional support with eventual enteral nutrition. NEHI is believed to be related to an increased number of neuroendocrine cells in airway epithelial area. These cells are abundant in foetal life, when they play a role in regulating the lung development and decrease before birth. There is no specific treatment for NEHI. The main treatment of chILD is corticosteroids. However, in NEHI, their efficacy is matter of debate. There is only a few NEHI cases series or cohorts all over the world, accounting for a maximum of 500 reported cases within only retrospective studies. Among them, United States and Argentina teams report supportive care only (oxygen therapy and nutritional support) whereas other teams, like the French ones largely uses IV corticosteroid pulses. Unlike the majority of chILD, NEHI prognosis is usually good. However, at school-age, 26% of the patients remain symptomatic or have an abnormal lung function. Moreover, oxygen therapy significantly affects quality of life (QoL) of the children with ILD (-10.43/100 points, p=0.02) but also QoL and mood of their parents (unpublished data). The present study hypothesis that corticosteroids are associated with a reduction of the length of oxygen support in infants with NEHI.
CONDITIONS
Official Title
Efficacy of Methylprednisolone Pulses in Neuroendocrine Celles Hyperplasia of Infancy : An Early Phase Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Infant aged under 12 months
- Diagnosis of NEHI based on a clinical Liptzin score 7 or higher with a suggestive chest CT pattern showing ground glass opacities in middle lobe, lingula, and paramediastinal areas, or clinical and CT suspicion plus lung biopsy showing increased neuroendocrine cells in airway epithelium
- Oxygen requirement during awake and/or asleep periods according to pediatric guidelines
- Followed in a RespiRare participating center
- Written informed consent from the legal representative at inclusion
You will not qualify if you...
- Other causes of childhood interstitial lung disease confirmed by lab tests, genetic analysis, bronchoalveolar lavage, or lung biopsy
- Previous treatment with intravenous methylprednisolone pulses at any time
- Diabetes
- Uncontrolled arterial hypertension
- Lack of health care insurance
- Current infection
- Received live attenuated vaccine within the past two weeks
- Long-term treatment with Azithromycin and/or Hydroxychloroquine
- Participation in another interventional clinical study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Pediatric Pulmonology Department and Reference centre for rare lung diseases
Paris, France, 75012
Actively Recruiting
Research Team
N
Nadia NATHAN
CONTACT
R
Ralph EPAUD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here